1. Home
  2. MRVI vs SABR Comparison

MRVI vs SABR Comparison

Compare MRVI & SABR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Maravai LifeSciences Holdings Inc.

MRVI

Maravai LifeSciences Holdings Inc.

HOLD

Current Price

$3.25

Market Cap

472.8M

Sector

Health Care

ML Signal

HOLD

Logo Sabre Corporation

SABR

Sabre Corporation

HOLD

Current Price

$1.57

Market Cap

580.9M

Sector

Technology

ML Signal

HOLD

Company Overview

Basic Information
Metric
MRVI
SABR
Founded
2014
2006
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Computer Software: Programming Data Processing
Sector
Health Care
Technology
Exchange
Nasdaq
Nasdaq
Market Cap
472.8M
580.9M
IPO Year
2020
2014

Fundamental Metrics

Financial Performance
Metric
MRVI
SABR
Price
$3.25
$1.57
Analyst Decision
Buy
Hold
Analyst Count
4
2
Target Price
$4.13
$2.50
AVG Volume (30 Days)
1.9M
5.1M
Earning Date
05-11-2026
05-06-2026
Dividend Yield
N/A
N/A
EPS Growth
14.29
283.56
EPS
N/A
1.34
Revenue
$185,743,000.00
$3,866,956,000.00
Revenue This Year
$12.44
$7.15
Revenue Next Year
$7.90
$3.40
P/E Ratio
N/A
$1.20
Revenue Growth
N/A
7.46
52 Week Low
$1.67
$0.81
52 Week High
$4.11
$3.46

Technical Indicators

Market Signals
Indicator
MRVI
SABR
Relative Strength Index (RSI) 57.59 55.34
Support Level $3.25 $1.45
Resistance Level $3.93 $1.70
Average True Range (ATR) 0.16 0.11
MACD 0.04 0.00
Stochastic Oscillator 86.11 70.18

Price Performance

Historical Comparison
MRVI
SABR

About MRVI Maravai LifeSciences Holdings Inc.

Maravai LifeSciences Holdings Inc is a life sciences company that provides critical products that drive the development of groundbreaking vaccines, drug therapies, cell and gene therapies, and diagnostics. The group's solutions empower research into human diseases and support the entire biopharmaceutical development process from early discovery to commercialization. Its reportable segments are Nucleic acid production and biologics safety testing. It generates a majority of its revenue from Nucleic Acid Production and focuses on the manufacturing and sale of nucleic acid products to support the needs of customers' research, and therapeutic and vaccine programs. In addition, the segment also provides research products for labeling and detecting proteins in cells and tissue samples.

About SABR Sabre Corporation

Sabre holds the number-two air booking volume share in the global distribution system industry. The distribution segment represented 80% of total 2025 revenue and airline IT solutions 20% of revenue. The company sold its growing hotel IT solutions division to TPG in 2025 for $960 million in net proceeds. Transaction fees, which are mostly tied to volume and not price, account for the bulk of sales and profits.

Share on Social Networks: